JP2017039702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017039702A5 JP2017039702A5 JP2016146928A JP2016146928A JP2017039702A5 JP 2017039702 A5 JP2017039702 A5 JP 2017039702A5 JP 2016146928 A JP2016146928 A JP 2016146928A JP 2016146928 A JP2016146928 A JP 2016146928A JP 2017039702 A5 JP2017039702 A5 JP 2017039702A5
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- crystalline form
- value
- resonance
- solid state
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001228 spectrum Methods 0.000 claims 12
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 7
- 238000001237 Raman spectrum Methods 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 6
- 239000012458 free base Substances 0.000 claims 6
- 238000004319 19F solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 5
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 claims 5
- 229950001290 lorlatinib Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US62/199418 | 2015-07-31 | ||
| US201662352349P | 2016-06-20 | 2016-06-20 | |
| US62/352349 | 2016-06-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017039702A JP2017039702A (ja) | 2017-02-23 |
| JP2017039702A5 true JP2017039702A5 (https=) | 2017-04-06 |
| JP6218253B2 JP6218253B2 (ja) | 2017-10-25 |
Family
ID=56686850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016146928A Active JP6218253B2 (ja) | 2015-07-31 | 2016-07-27 | ロルラチニブ遊離塩基の結晶形態 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (https=) |
| EP (2) | EP3798222B1 (https=) |
| JP (1) | JP6218253B2 (https=) |
| KR (1) | KR102088188B1 (https=) |
| CN (3) | CN116063322A (https=) |
| AU (1) | AU2016304420B2 (https=) |
| BR (1) | BR112017028604A2 (https=) |
| CA (1) | CA2937257C (https=) |
| CY (1) | CY1123689T1 (https=) |
| DK (2) | DK3798222T3 (https=) |
| ES (2) | ES2842302T3 (https=) |
| FI (1) | FI3798222T3 (https=) |
| HK (1) | HK1252845A1 (https=) |
| HU (2) | HUE065536T2 (https=) |
| MX (2) | MX382600B (https=) |
| PL (2) | PL3798222T3 (https=) |
| PT (2) | PT3798222T (https=) |
| RU (1) | RU2018101363A (https=) |
| SG (1) | SG10201913200XA (https=) |
| SI (2) | SI3798222T1 (https=) |
| TW (1) | TWI616449B (https=) |
| WO (1) | WO2017021823A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6783311B2 (ja) | 2015-09-24 | 2020-11-11 | サイクレニウム ファーマ インコーポレーテッド | ヘテロアリール含有大環状化合物のライブラリならびにその製造方法および使用方法 |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| JP2020524701A (ja) * | 2017-06-22 | 2020-08-20 | サイクルニウム ファーマ インコーポレイテッド | ピリジン含有大環状化合物ライブラリーならびにその製造および使用方法 |
| JP7153069B2 (ja) | 2017-10-10 | 2022-10-13 | ファイザー・インク | ロルラチニブ遊離塩基水和物の結晶形態 |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| US20210163498A1 (en) | 2018-04-23 | 2021-06-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| WO2020148635A1 (en) * | 2019-01-17 | 2020-07-23 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
| EP3999514A1 (en) | 2019-07-18 | 2022-05-25 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| CN110530998A (zh) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2566858A2 (en) | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| HUE034118T2 (en) * | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| CA2916605C (en) * | 2013-06-28 | 2018-04-24 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| JP7153069B2 (ja) | 2017-10-10 | 2022-10-13 | ファイザー・インク | ロルラチニブ遊離塩基水和物の結晶形態 |
-
2016
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
- 2016-07-27 HU HUE20202336A patent/HUE065536T2/hu unknown
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/pl unknown
- 2016-07-27 ES ES16751665T patent/ES2842302T3/es active Active
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en not_active Ceased
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/ru unknown
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/zh active Pending
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 MX MX2018001324A patent/MX382600B/es unknown
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/hu unknown
- 2016-07-27 ES ES20202336T patent/ES2972010T3/es active Active
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/ko active Active
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/zh active Pending
- 2016-07-27 HK HK18112176.1A patent/HK1252845A1/zh unknown
- 2016-07-27 MX MX2021002220A patent/MX395263B/es unknown
- 2016-07-27 SI SI201631780T patent/SI3798222T1/sl unknown
- 2016-07-27 TW TW105123769A patent/TWI616449B/zh active
- 2016-07-27 PT PT202023362T patent/PT3798222T/pt unknown
- 2016-07-27 PL PL16751665T patent/PL3328867T3/pl unknown
- 2016-07-27 SI SI201631027T patent/SI3328867T1/sl unknown
- 2016-07-27 CN CN202310214099.4A patent/CN116063323A/zh active Pending
- 2016-07-27 PT PT167516657T patent/PT3328867T/pt unknown
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/fi active
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/da active
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/da active
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/pt not_active Application Discontinuation
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/ja active Active
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017039702A5 (https=) | ||
| JP2020536893A5 (https=) | ||
| JP2015010091A5 (https=) | ||
| RU2018101363A (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2013520424A5 (https=) | ||
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| JP2011168587A5 (https=) | ||
| WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| WO2016160617A3 (en) | Inhibitors of cyclin-dependent kinases | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2020511467A5 (https=) | ||
| TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
| NZ602271A (en) | Bicyclic compounds and their uses as dual c-src / jak inhibitors | |
| WO2016105528A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| JP2016065042A5 (https=) | ||
| WO2009132202A3 (en) | Macrocyclic compounds and their use as kinase inhibitors | |
| JP2016537382A5 (https=) | ||
| RU2015103065A (ru) | Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения | |
| JP2013522325A5 (https=) | ||
| MX355436B (es) | Sal novedosa de abexinostato, forma cristalina asociada, método de preparacion de la misma y las composiciones farmaceuticas que contienen la misma. | |
| PH12014501832A1 (en) | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | |
| JP2016204373A5 (https=) | ||
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| JP2009541344A5 (https=) |